Barclays Begins Coverage on Bruker (NASDAQ:BRKR)

Investment analysts at Barclays began coverage on shares of Bruker (NASDAQ:BRKR) in a report released on Tuesday, Marketbeat Ratings reports. The brokerage set an “overweight” rating and a $75.00 price target on the medical research company’s stock. Barclays‘s target price would suggest a potential upside of 22.41% from the company’s current price.

A number of other brokerages have also recently issued reports on BRKR. The Goldman Sachs Group decreased their target price on Bruker from $72.00 to $60.00 and set a “sell” rating for the company in a research report on Tuesday, July 9th. TD Cowen lowered their target price on shares of Bruker from $74.00 to $72.00 and set a “hold” rating on the stock in a research report on Wednesday, August 7th. Citigroup cut their target price on shares of Bruker from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Wednesday, July 10th. Wolfe Research cut shares of Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. Finally, Wells Fargo & Company started coverage on shares of Bruker in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $78.00 price objective on the stock. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $80.82.

Bruker Stock Performance

Shares of Bruker stock opened at $61.27 on Tuesday. The firm has a market capitalization of $8.90 billion, a P/E ratio of 22.28, a P/E/G ratio of 2.52 and a beta of 1.18. The company has a quick ratio of 0.75, a current ratio of 1.65 and a debt-to-equity ratio of 1.18. Bruker has a 52 week low of $53.79 and a 52 week high of $94.86. The firm’s 50 day moving average is $65.15 and its two-hundred day moving average is $69.44.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Tuesday, August 6th. The medical research company reported $0.52 EPS for the quarter, hitting the consensus estimate of $0.52. Bruker had a net margin of 11.29% and a return on equity of 24.92%. The firm had revenue of $800.70 million for the quarter, compared to analyst estimates of $799.44 million. During the same period last year, the business earned $0.50 EPS. Bruker’s revenue for the quarter was up 17.4% compared to the same quarter last year. Research analysts forecast that Bruker will post 2.61 EPS for the current fiscal year.

Institutional Trading of Bruker

Several hedge funds have recently modified their holdings of BRKR. Rheos Capital Works Inc. acquired a new position in Bruker during the third quarter worth $3,453,000. Covea Finance acquired a new position in shares of Bruker during the 3rd quarter worth $1,568,000. UMB Bank n.a. grew its stake in shares of Bruker by 115.3% during the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock worth $46,000 after purchasing an additional 354 shares during the period. CWM LLC increased its holdings in shares of Bruker by 191.9% in the 3rd quarter. CWM LLC now owns 13,942 shares of the medical research company’s stock valued at $963,000 after purchasing an additional 9,165 shares in the last quarter. Finally, GAMMA Investing LLC lifted its stake in shares of Bruker by 81.0% in the third quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock valued at $60,000 after purchasing an additional 388 shares during the period. 79.52% of the stock is owned by institutional investors and hedge funds.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.